West Completes $80-Million Manufacturing Expansion to Support Diabetes & Obesity Treatments for Patients Worldwide


West Pharmaceutical Services, Inc. recently announced it has completed an $80-million capacity expansion at its Contract Manufacturing site in Grand Rapids, MI. This investment will extend production and accessibility for patient-centric diabetes and obesity products, in response to increasing demand from West’s customers for device and drug delivery manufacturing solutions to support chronic disease treatments.

“West is proud to continue to support our customers in addressing the ever-changing landscape of healthcare. With a growing obesity and diabetes epidemic, this expansion will further support our customers’ device manufacturing requirements, helping to ensure reliable supply for these critical treatments today and in the future,” Aileen Ruff, President, Contract Manufacturing at West, said.

As the needs of healthcare are evolving for more patient-focused drug delivery solutions, access to development and commercialization services to help bring these products to market becomes increasingly critical. West has invested globally to support these drug delivery requirements, and this most recent manufacturing investment in Grand Rapids reflects West’s strategy of meeting its customers’ growing needs with both product and service offerings.

West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites worldwide, West helps support our customers by delivering approximately 43 billion components and devices each year. Headquartered in Exton, PA, West in its fiscal year 2023 generated $2.95 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor’s 500 index. For more information, visit www.westpharma.com.